Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Add To Watchlist

Recent & Breaking News (NDAQ:GILD)

European CHMP Adopts Positive Opinion for Gilead's TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV

Business Wire April 29, 2016

Gilead Sciences Announces Second Quarter 2016 Dividend

Business Wire April 28, 2016

Gilead Sciences Announces First Quarter 2016 Financial Results

Business Wire April 28, 2016

Sustainable Investing With A New ETF

Benzinga.com April 25, 2016

European Commission Grants Marketing Authorization for Gilead's Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Business Wire April 25, 2016

Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016

Business Wire April 21, 2016

Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies

Business Wire April 16, 2016

Gilead Presents New Data Highlighting Progress in Liver Fibrosis

Business Wire April 16, 2016

Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection

Business Wire April 15, 2016

U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead's Third TAF-Based HIV Therapy

Business Wire April 4, 2016

Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases

Business Wire April 4, 2016

Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection

Business Wire March 31, 2016

Potent Value In This Large-Cap ETF

Benzinga.com March 18, 2016

A Rare Opportunity With A Biotechnology ETF

Benzinga.com March 17, 2016

Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 15

Business Wire March 10, 2016

Factor Fun With This ETF

Benzinga.com March 10, 2016

Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016

Business Wire March 4, 2016

Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7

Business Wire March 4, 2016

U.S. Food and Drug Administration Approves Gilead's Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Business Wire March 1, 2016

Health Canada Issues Notice of Compliance for Gilead's Truvada® for Reducing the Risk of Sexually Acquired HIV Infection

Canada NewsWire February 29, 2016